Latest news with #RGEN
Yahoo
25-06-2025
- Business
- Yahoo
5 Insightful Analyst Questions From Repligen's Q1 Earnings Call
Repligen's first quarter results for 2025 saw revenue and adjusted profits exceed Wall Street expectations, but the market reacted negatively, reflecting investor caution. Management attributed growth to strong demand across its protein, chromatography, and analytics product lines, as well as robust order momentum in biopharma manufacturing. CEO Olivier Loeillot highlighted that "orders were up high teens year on year with all franchises growing double digits," and noted particularly strong performance from consumables and proteins. However, capital equipment sales faced headwinds due to timing and customer delays, while small biotech sales softened, highlighting ongoing uncertainty in that segment. Is now the time to buy RGEN? Find out in our full research report (it's free). Revenue: $169.2 million vs analyst estimates of $164.3 million (10.4% year-on-year growth, 3% beat) Adjusted EPS: $0.39 vs analyst estimates of $0.35 (11.4% beat) Adjusted EBITDA: $32.7 million vs analyst estimates of $28.78 million (19.3% margin, 13.6% beat) The company lifted its revenue guidance for the full year to $707.5 million at the midpoint from $697.5 million, a 1.4% increase Management lowered its full-year Adjusted EPS guidance to $1.67 at the midpoint, a 2.3% decrease Operating Margin: 3.9%, up from 2.4% in the same quarter last year Organic Revenue rose 10.7% year on year (-12.5% in the same quarter last year) Market Capitalization: $6.75 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Rachel Vatnsdal (JPMorgan) asked whether tariffs led to order pull-forward and about the sustainability of CDMO order strength. CEO Olivier Loeillot replied there was no evidence of customers accelerating purchases and that CDMO growth was broad-based, especially in ATF consumables. Dan Arias (Stifel) inquired about emerging modalities and potential impacts from FDA changes. Loeillot confirmed new modalities revenue and orders rose, and reported no signs of trial disruptions or slowdowns from regulatory changes. Puneet Souda (Leerink Partners) questioned the clinical versus commercial revenue mix's sustainability and the integration of 908 Devices. Loeillot explained the mix remains stable but is gradually shifting commercial, and integration efforts are focused on R&D and commercial synergy. Jacob Johnson (William Blair) asked about small biotech trends. Loeillot acknowledged sales to small biotech declined due to weak funding, but this segment now represents less than 10% of Repligen's business. Justin Bowers (Deutsche Bank) asked about the impact of biopharma onshoring and margin outlook. Loeillot highlighted that increased U.S. manufacturing capacity could be a tailwind, and Garland noted Q1 gross margin benefited from product mix that is unlikely to repeat. In the coming quarters, the StockStory team will be watching (1) the pace of adoption for new analytics and mixing technologies, (2) the trajectory of order growth among large pharma, CDMO, and emerging modalities, and (3) signs of stabilization or recovery in small biotech and China segments. Progress on integrating recent acquisitions and managing tariff-related risks will also be important markers for execution. Repligen currently trades at $123.96, down from $143.71 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
Yahoo
03-05-2025
- Business
- Yahoo
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits. Right now, Qiagen is sporting a Zacks Rank of #2 (Buy), while Repligen has a Zacks Rank of #4 (Sell). Investors should feel comfortable knowing that QGEN likely has seen a stronger improvement to its earnings outlook than RGEN has recently. But this is just one piece of the puzzle for value investors. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use. QGEN currently has a forward P/E ratio of 18.61, while RGEN has a forward P/E of 81.50. We also note that QGEN has a PEG ratio of 2.40. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. RGEN currently has a PEG ratio of 3.91. Another notable valuation metric for QGEN is its P/B ratio of 2.63. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, RGEN has a P/B of 3.88. Based on these metrics and many more, QGEN holds a Value grade of B, while RGEN has a Value grade of D. QGEN is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that QGEN is likely the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
03-05-2025
- Business
- Yahoo
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025. In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Repligen Corporation (NASDAQ:RGEN). Repligen Corporation (NASDAQ:RGEN) develops and distributes bioprocessing technologies and systems. The one-month return of Repligen Corporation (NASDAQ:RGEN) was 22.57%, and its shares lost 17.87% of their value over the last 52 weeks. On May 1, 2025, Repligen Corporation (NASDAQ:RGEN) stock closed at $137.20 per share with a market capitalization of $7.708 billion. Conestoga Capital Advisors stated the following regarding Repligen Corporation (NASDAQ:RGEN) in its Q1 2025 investor letter: "Repligen Corporation (NASDAQ:RGEN) is a provider of tools used by biotechnology companies. RGEN reported in-line Q4 2024 results and 2025 guidance. The stock rose on the earnings release but fell later in the quarter on rising uncertainty related to U.S. Federal Government spending on healthcare initiatives. Companies with exposure to the bio-processing industry remained under pressure during the first quarter of 2025. We maintain our high conviction in RGEN as we believe there are indications of improving fundamentals for the business." A technician in a lab inspecting an ELISA test kit for use in biopharmaceutical diagnostics. Repligen Corporation (NASDAQ:RGEN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held Repligen Corporation (NASDAQ:RGEN) at the end of the fourth quarter, compared to 34 in the third quarter. While we acknowledge the potential of Repligen Corporation (NASDAQ:RGEN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Repligen Corporation (NASDAQ:RGEN) and shared the list of the best-performing stocks from the last 20 years, as listed by Jim Cramer. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
30-04-2025
- Business
- Yahoo
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company's full-year revenue guidance of $707.5 million at the midpoint came in 0.8% above analysts' estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts' consensus estimates. Is now the time to buy RGEN? Find out in our full research report (it's free). Revenue: $169.2 million vs analyst estimates of $164.3 million (10.4% year-on-year growth, 3% beat) Adjusted EPS: $0.39 vs analyst estimates of $0.35 (11.4% beat) Adjusted EBITDA: $32.7 million vs analyst estimates of $28.78 million (19.3% margin, 13.6% beat) The company lifted its revenue guidance for the full year to $707.5 million at the midpoint from $697.5 million, a 1.4% increase Management lowered its full-year Adjusted EPS guidance to $1.67 at the midpoint, a 2.3% decrease Operating Margin: 3.9%, up from 2.4% in the same quarter last year Free Cash Flow Margin: 9.1%, down from 23.7% in the same quarter last year Organic Revenue rose 10.7% year on year (-12.9% in the same quarter last year) Market Capitalization: $7.83 billion Repligen's first quarter results were driven by double-digit organic revenue growth, with particular strength in proteins, chromatography, and analytics. Management attributed performance to broad-based demand from large pharma and contract manufacturers, robust order growth across product lines, and continued resilience in core bioprocessing markets. CEO Olivier Loeillot highlighted, 'Orders were up high teens year on year with all franchises growing double digits,' and noted the company's ability to secure new design wins in late-phase and commercial drugs as a significant tailwind. Looking forward, Repligen raised its annual revenue guidance while lowering non-GAAP earnings expectations, reflecting the inclusion of recent acquisitions and anticipated margin headwinds from tariffs and investment in operating expenses. While management believes tariff exposure is limited, CFO Jason Garland clarified, 'We believe that it's probably less than 1% sales increase that we would have from tariffs,' and outlined measures to mitigate further impacts. The company's emphasis on R&D, product launches, and a diversified customer base remain central to its growth strategy. Repligen's Q1 outperformance stemmed from strong demand in key franchises, broad-based order momentum, and recent product innovation. Management discussed how strategic execution and industry tailwinds contributed to results, while also addressing evolving trade and regulatory dynamics. Protein Franchise Growth: The protein business delivered the highest growth among all segments, driven by commercial demand and strong chromatography resin sales. Management noted that some timing benefits may not repeat in future quarters. Chromatography and Analytics Expansion: Both chromatography and analytics franchises saw double-digit growth, supported by increased adoption of large-scale columns and expansion into new customer segments, such as large pharmaceutical companies. Order Momentum Across End Markets: Orders rose by high teens year over year, with especially strong intake from contract development and manufacturing organizations (CDMOs), which saw order growth above 40%. The company noted no evidence of order pull-forward due to tariffs, suggesting underlying demand was robust. Tariff and Supply Chain Management: Management estimated limited tariff exposure, with most U.S. manufacturing insulated from duties. Steps to mitigate tariff risk include leveraging global manufacturing, pricing adjustments, and operational flexibility, particularly for European and Asian markets. Acquisition and Innovation Initiatives: Repligen closed the acquisition of 908 Devices' bioprocessing portfolio, accelerating process analytics offerings. Integration efforts are focused on R&D synergies and manufacturing optimization, with new product launches such as the Metanova-based MixOne mixer receiving positive customer feedback. Management's outlook centers on sustaining above-market growth through portfolio innovation, diversified end-markets, and operational discipline, while monitoring macroeconomic and regulatory risks. New Product Integration: The integration of 908 Devices' portfolio and continued R&D investment are expected to drive analytics segment growth and future product launches, broadening Repligen's addressable market. Customer and End-Market Diversification: The company's focus on expanding relationships with large pharma, CDMOs, and capturing commercial drug opportunities is expected to support resilient revenue streams even as small biotech end-markets remain challenged. Tariff and Margin Pressures: While management anticipates only modest gross margin headwinds from tariffs, ongoing inflation and potential trade volatility remain risks. The company's strategy of global manufacturing and pricing adjustments will be critical to sustaining profitability. Rachel Vatnsdal (JPMorgan): Asked if recent CDMO order strength reflected any pull-forward due to tariffs; management said there was no evidence of accelerated ordering, with growth broad-based across products and customers. Dan Arias (Stifel): Questioned the impact of FDA and regulatory changes on new modalities; management reported minimal disruption so far and maintained a positive long-term outlook for cell and gene therapy demand. Puneet Souda (Leerink Partners): Inquired about sustainability of growth between clinical and commercial segments; management explained that commercial revenue is steadily increasing, with a projected shift toward a 50/50 split over several years. Matt Larew (William Blair): Sought detail on small biotech customer trends; management acknowledged sales weakness and flat orders from this segment, citing declining biotech funding as a key concern. Justin Bowers (Deutsche Bank): Asked about the impact of large biopharma onshoring and CapEx; management expects these trends to benefit Repligen given its U.S. manufacturing base and strong customer relationships. In the coming quarters, the StockStory team will monitor (1) the pace of new product rollouts, especially analytics and single-use technologies, (2) order and sales trends among large pharma and contract manufacturers to gauge demand durability, and (3) the company's margin trajectory amid ongoing tariff and cost pressures. Execution on R&D integration and manufacturing optimization from recent acquisitions will also be key indicators of Repligen's ability to sustain above-market growth. Repligen currently trades at a forward P/E ratio of 74.7×. Should you double down or take your chips? The answer lies in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Washington Post
29-04-2025
- Business
- Washington Post
Repligen: Q1 Earnings Snapshot
WALTHAM, Mass. — WALTHAM, Mass. — Repligen Corp. (RGEN) on Tuesday reported first-quarter net income of $5.8 million. On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 10 cents. Earnings, adjusted for one-time gains and costs, were 39 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 35 cents per share.
